Kytopen Company
Kytopen developer of a cell therapy platform for non-viral delivery of molecules into hard-to-transfect immune cells.
Technology:
Bioengineering
Industry:
Gene therapy, Private
Headquarters:
Cambridge, Massachusetts, United States
Founded Date:
2017-01-01
Employees Number:
11-50
Funding Status:
Early Stage Venture
Investors Number:
13
Total Funding:
37118461
Last Funding Date:
2021-09-28
Last Funding Type:
Series A
Register and Claim Ownership